Medpace Holdings, Inc. (MEDP) Interest Coverage Ratio: N/A
The interest coverage ratio for Medpace Holdings, Inc. (MEDP) is N/A as of Wednesday, June 17, 2026.
MEDP Interest Coverage Ratio Metrics
INTEREST COVERAGE RATIO
N/A
MEDP Competitors' Interest Coverage Ratio
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | N/A | N/A | N/A | N/A |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 6.83x | 6.50x | 6.73x | 9.55x |
| Solventum Corporation (SOLV)vs › | $12.91B | 6.29x | 4.55x | 4.55x | 4.55x |
| Align Technology, Inc. (ALGN)vs › | $12.86B | N/A | 67.41x | 66.08x | 407.22x |
| DaVita Inc. (DVA)vs › | $13.46B | 3.66x | 4.05x | 3.97x | 4.62x |
| Revvity, Inc. (RVTY)vs › | $10.91B | 3.87x | 4.06x | 4.92x | 8.88x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -29.20x | 3.03x | 3.75x | 5.52x |
| Baxter International Inc. (BAX)vs › | $10.19B | -1.06x | 0.71x | 2.65x | 6.89x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 16.73x | 11.98x | 11.81x | 13.87x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 4.74x | 3.27x | 5.51x | 5.84x |
Financial Health Indicators
Interest Coverage
N/A
Debt/Equity
0.55
Current Ratio
0.74
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
- < 1.5x: EBIT is less than 1.5 times interest expense
- 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
- 3x - 5x: EBIT is between 3 and 5 times interest expense
- > 5x: EBIT is more than 5 times interest expense
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Medpace Holdings, Inc. Interest Coverage Ratio Formula & Definition
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle